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Abstract Myogenin, a member of the MyoD family which governs skeletal muscle differentiation, was identified as a pair of phosphorylated bands 
on SDS-PAGE during myogenesis. The slow migrating form was found to be hyperphosphorylated myogenin. In vitro phosphorylation by CDC2 
kinase caused a prominent reduction in electrophoretic mobility of myogenin. Furthermore, we demonstrated that phosphorylation of the serine 
residue at position 43 contributes to the modification of myogenin in vivo and in vitro resulting in the reduction in electrophoretic mobility. We 
propose here that a CDCZ-like proline-directed kinase regulates myogenin activity through its phosphorylation. 
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1. Introduction 
Myogenic determining factors including MyoDl, myogenin, 
Myf.5, and MRF4, play a crucial role in the determination and 
terminal differentiation of myogenic cell lineage [l-7]. Gene 
disruption experiments have demonstrated that myogenin func- 
tion is essential for myogenic differentiation and cannot be 
compensated for by other MyoD family members [8,9]. Thus, 
the regulation of myogenin function appears to be crucial for 
the terminal differentiation of myogenic cells. Myogenin activ- 
ity is regulated at the post-translational level as well as the 
transcriptional level as shown for other myogenic determining 
factors (reviewed in [lo]). 
We have identified differentiating myoblasts as myogenin- 
positive mononucleated cells (Hashimoto et al., submitted). 
Terminal differentiation of differentiating myoblasts is can- 
celed by growth factors, oncogene products, and chemical rea- 
gents modifying the phosphorylation state of cellular proteins 
([ll-191, Hashimoto et al., submitted). Thus, the decision be- 
tween proliferation and differentiation would be made in differ- 
entiating myoblasts. It is conceivable that post-translational 
modification of myogenin is important for its activity and for 
switching from proliferation to terminal differentiation. In fact, 
calcium-dependent protein kinase (PKC) [20] and CAMP-de- 
pendent protein kinase (PKA) [21] phosphorylate overex- 
pressed myogenin in non-myogenic cells (COS-1). However, it 
is unclear whether the phosphorylation of myogenin by PKC 
or PKA plays a role in myogenic differentiation. During myo- 
genesis, myogenin is detected as a pair of bands on SDS-PAGE 
([22]; Hashimoto et al., submitted) of which the slow migrating 
band is assumed to be a phosphorylated form. However, the 
phosphorylation state of myogenin in differentiating myoblasts 
and myotubes has not been described. Here we identify myo- 
genin in myogenic cells as a pair of differentially phosphory- 
lated forms with different electrophoretic mobilities. The slow 
migrating band is a hyperphosphorylated form whose mobility- 
shift implies a significant structural change in the myogenin 
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protein, that is expected to affect its function. We found that 
CDC2 kinase, initially reported as a cytoplasmic cell cycle reg- 
ulator in various animals [23-271, shifts the electrophoretic mo- 
bility of myogenin through phosphorylation in vitro. Further- 
more, we determine the phosphorylation site responsible for the 
electrophoretic mobility-shift of myogenin by site-directed mut- 
agenesis. This phosphorylation of myogenin may be important 
in the post-translational regulation of myogenin function dur- 
ing myogenesis. 
2. Materials and methods 
2.1. Cell culture and transfection 
C2C12, lOT1/2, and COS-7 cells were maintained in growth medium 
consisting of Dulbecco’s modified Eagle’s minimum essential medium 
with 4.5 g/l glucose (DMEM) supplemented with 10% fetal calf serum 
(FCS; HyClone) under a humidified atmosphere containing 10% CO,. 
For the induction of myogenic differentiation, the cells were cultured 
in DMEM plus 2% horse serum (HS/DMEM). lOT1/2 cells were trans- 
fected by calcium phosphate precipitation [28]. Wild type or mutant rat 
myogenin cDNA [7] was subcloned into the EcoRI site of an expression 
vector, pcDLSRa296 [29], and cotransfected to lOT112 cells with 
pSV2brs ([30]; Funakoshi Co., Tokyo). Myogenin-expressing cell 
clones were selected and maintained in DMEM supplemented with 10% 
FCS and blasticidin S-hydrochloride (4&ml; Funakoshi Co., Tokyo). 
COS-7 cells were transiently transfected with myogenin expression plas- 
mids using a transfection reagent, DOTAP (Boeringer Mannheim Bio- 
chemica). Cells were harvested 3 days later for immunoblotting as 
described (Hashimoto et al., submitted). 
2.2. In vivo labeling and immunoprecipitation 
C2Cl2 cells were cultured in growth medium to 70% confluence at 
which time the medium was switched to HYDMEM. Four days later 
myotube cultures were labeled with 0.25 mCi/ml [“Plorthophosphate 
(ICN Radiochemicals) for 4 h. Dishes were then rinsed 3 times with 
HEPES-buffered saline (10 mM HEPES-NaOH, pH7.4, 150 mM 
NaCI). After adding 200 ,uI of RIPA buffer (10 mM HEPES-NaOH, 
pH 7.2, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 
0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 10 &ml aprotinin, 
10 mM EDTA, 2.5 mM EGTA, 10 mM NaF, 5 mM sodium pyro- 
phosphate, 0.1 mM sodium orthovanadate), the cells were scraped and 
sonicated. Following 10 min centrifugation, the supernatant was frozen 
in liquid nitrogen and stored at -80°C until use. An aliquot of superna- 
tant (120 ~1) was precleared with 20~1 of 10% formalin-fixed Staphylo- 
coccus aureus (SA) conjugated with normal rabbit IgG. The precleared 
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supernatant was equally divided into two tubes and incubated for 1 h 
on ice with 20 ~1 of 10% SA-conjugated with affinity-purified rabbit 
anti-myogenin antibody (Hashimoto et al., submitted) or anti-GTPase- 
activating protein (GAP) C-terminal peptide antibody as a control [31]. 
After centrifugation, the pellets were washed 3 times with RIPA buffer 
and then boiled in two-times concentrated SDS (2 x SDS) sample 
buffer. Labeled proteins were resolved by 15% SDS polyacrylamide gel 
electrophoresis (acrylamide : methylene bis-acrylamide = 300: 1.7) and 
electrotransferred topolyvinylidine difluoride membranes (Trans-Blot, 
Bio-Rad). Labeled proteins were detected with a Fuji Image Analyzer 
BAS 2000 and then membranes were probed with anti-myogenin anti- 
body followed by probing with a swine anti-rabbit IgG conjugated with 
alkaline phosphatase (Dako) as described elsewhere (Hashimoto et al., 
submitted). 
2.3. In vitro transcription and translation 
Rat myogenin cDNA [q was subcloned into the EcoRI site of 
Bluescript II (Stratagene). Myogenin mRNA was transcribed in vitro 
using 2 pg of linearized plasmid according to the manufacturer’s recom- 
mendations (Stratagene, mRNA Capping Kit). One pg of myogenin 
mRNA was translated with rabbit reticulocyte lysate in a 5O;ul reaction 
volume containing [“Slcysteine (ICN Radiochemicals) or cold cysteine 
according to the manufacturer’s recommendations (Promega). 
2.4. In vitro phosphorylation 
[“S]Cysteine-labeled myogenin (3 ~1) was phosphorylated by incu- 
bation at 30°C for up to 60 min in a iO-,~l reaction mixture coniaining 
50 mM Tris-HCI, pH 8.0, 50 mM sodium B-glycerophosphate, 10 mM 
MgCI,, 1 mM DTT, 0.1 mM EGTA, 1 mM ATP, and purified cyclin 
B/CDCZ complex. The reaction was terminated by adding 2.5 ~1 of 
5 x SDS samnle buffer. Labeled mvogenin was resolved bv SDS-PAGE 
and detected-with an Image Analyzer. The cyclin B/CDC2 complex was 
purified from starfish oocytes as described previously [32,33]. Briefly, 
starfish oocytes perfectly synchronized at the first meiotic metaphase 
were crushed and the cyclin B/CDCZ complex was purified from a 
soluble fraction by a ~13”“” -affinity column chromatography. The 
preparation does not contain cyclin AICDC2 complex. 
The following synthetic peptides were used as substrates for in vitro 
phosphorylation: MP3b (RRHSASCSPEWGNALE), Kemptide 
(CAMP-dependent protein kinase substrate, LRRASLG), and casein 
kinase II substrate (RRREEETEEE). Active CDC2 kinase was incu- 
bated with 500 PM peptide at 30°C ‘for up to 60 min in the presence 
of 50 uM ATP (1 uCi of I’ZP-rlATPIIO ul reaction volume1. After _ , , A 
incubation, 8 ,uI of reaction’mixture was spotted on phosphocellulose 
paper, washed 3 times with 1% phosphoric acid, and air-dried. The 
radioactivity on the filter was measured with a liquid scintillation 
counter in the presence of scintillator. 
2.5. Chemical cleavage and phosphopeptide analysis 
Myogenin translated in vitro (100 ~1) was uhosuhorvlated for 1 h as 
described above in a 200 ,~l ieaciion vol;me con&ining 100 ,&i 
lr-“PlATP (New England Nuclear. Radiochemicals. 4500 Ci/mmol1. 
The reaction was terminated by adhing 4 ~1 of 2.5 AM staurosporine 
(Sekagakukougyou, Tokyo). Myogenin was immunoprecipitated with 
anti-myogenin antibody as described. Immunoprecipitates from 5 inde- 
pendent reactions were pooled, separated on SDS-PAGE, and trans- 
ferred onto nitrocellulose membranes (Schleicher and Schuell, Dassel). 
Phosphorylated proteins detected with an Image Analyzer were excised 
and cleaved by N-chlorosuccinimide ssentially as described by Lischwe 
and Sung [34]. The cleaved peptides were lyophilized, dissolved in 
peptide gel sample buffer (4% SDS, 50 mM Tris-HCI, pH 6.8, 50% 
glycerol, 2% /?-mercaptoethanol), and boiled for 5 min. Peptides were 
separated on Tricine-SDS-PAGE ([35], AC1 Japan Co., Kanagawa). 
2.6. Site-directed mutagenesis 
Site-directed mutagenesis was performed with single-stranded DNA 
templates according to the manufacturer’s recommendations (Strat- 
agene, Mutator DNA polymerase III site-directed mutagenesis kit). 
Mutants were generated with the following oligonucleotides identical 
to the antisense chain: 
SIA, CTG, GTA, GAA, ATA, GGG, GGC, TGT, T-K, ATA, CAG, CTC 
S43G, CCC, TCG, GGC, ‘l-K, CGG, GCC, TAA, GCT, GAG, CTC 
T5lA, TGG, ACA, ATG, CTC, AGG, GGC, CCC, CAG, TCC, Cm 
S170A, ATT, GCC, CCA, CTC, CGG, TGC, GCA, GGA, GGC, GCI- 
All mutations and coding regions included in the templates were 
confirmed by DNA sequencing. 
3. Results 
3.1. Myogenin is phophorylated at multiple sites during 
myogenesis 
Myogenin was detected as a pair of bands during the myo- 
genesis of C2C12 cells by immunoblotting (Fig. 1, lane 4) and 
the slow migrating band on SDS-PAGE is assumed to be 
phosphorylated form [22]. However, direct evidence for the 
phosphorylation of myogenin during myogenesis has not been 
reported. Thus, C2C12 myotubes were labeled with [32P]ortho- 
phosphate and the cellular myogenin was immunoprecipitated 
with an affinity purified anti-myogenin antibody (Hashimoto 
et al., submitted). Immunoprecipitates were separated on SDS- 
PAGE and then electrotransferred to PVDF membranes. A 
pair of phosphorylated bands was detected with an Image An- 
alyzer (Fig. 1, lane 2) and the membrane was probed with 
anti-myogenin antibody (Fig. 1, lane 4). The electrophoretic 
mobility of a pair of phosphorylated bands (Fig. 1, lane 2) was 
identical to that of the myogenin band pair (Fig. 1, lane 4). The 
results clearly show that both the slow migrating form and the 
fast migrating form of myogenin are phosphorylated in vivo. 
The protein ratio of the fast-to-slow migrating forms was ap- 
proximately 4 : 1 whereas their ratio of phosphate incorporation 
was approximately 1: 1. Thus, the slow migrating band is a 
hyperphosphorylated form. 
3.2. CDC2 kinase phosphorylates myogenin and reduces its 
electrophoretic mobility in vitro 
PKA [21] and PKC [20] have been reported to phosphorylate 
myogenin, although neither kinase mimics the electrophoretic 
mobility-shift that occurs in vivo. CDC2 kinase is another can- 
didate for the modification of myogenin that results in the 
reduction of electrophoretic mobility because myogenin con- 
32P anti-myogenin 
1 2 3 4 
Fig. 1. Phosphorylation of myogenin in myotubes. Myogenin im- 
munoprecipitates from “P-labeled C2C12 myotube lysates were sepa- 
rated on SDS-PAGE, and electrotransferred to a PVDF membrane. 
After the detection of radioactivity (lanes 1 and 2), myogenin was 
detected with affinity purified anti-myogenin antibody (lanes 3 and 4). 
Lanes 1 and 3, immunoprecipitates with anti-rasGAP antibody as an 
unrelated antibody. Lanes 2 and 4, immunoprecipitates with anti-myo- 
genin antibody. Asterisk, heavy chain of immunoglobulin used for 
immunoprecipitation. Arrows represent myogenin as a pair of bands. 
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Fig. 2. The reduction of electrophoretic mobility of myogenin through in vitro phosphorylation by CDC2 kinase. (A) Reduction in the electrophoretic 
mobility of myogenin as a function of incubation time with active CDC2 kinase. “S-Labeled myogenin was phosphorylated by CDC2 kinase in vitro 
for the indicated periods and analyzed on SDS-PAGE. (B) Repression of the electrophoretic mobility-shift of myogenin by protein kinase inhibitors. 
Phosphorylation was carried out at 30°C for 60 min. Reaction mixtures contained: lane 1, reticulocyte lysate without myogenin RNA, CDC2 kinase, 
and 1 mM ATP; lane 2, reticulocyte lysate with myogenin RNA, CDC2 kinase, and 1 mM ATP; lane 3, reticulocyte lysate with myogenin RNA 
and 1 mM ATP; lane 4, reticulocyte lysate with myogenin RNA, CDC2 kinase, 1 mM ATP, and 50 PM staurosporine; lane 5, reticulocyte lysate 
with myogenin RNA, CDC2 kinase, 1 mM ATP, and 1 mM 6-dimethylaminopurine. The positions of molecular weight markers are shown on the 
left. 
tains four serine-proline (SP) and threonine-proline (TP) se- 
quences as possible phosphorylation sites for CDC2 kinase 
[36,37]. CDC2 kinase has been reported to reduce the electro- 
phoretic mobility of neurofilaments on SDS-PAGE [33]. Thus, 
[35S]cysteine-labeled myogenin produced by in vitro translation 
was incubated with active CDC2 kinase in the presence of 
1 mM ATP and analyzed on SDS-PAGE. The electrophoretic 
mobility of myogenin was reduced from 36 kDa to 38 kDa in 
an incubation time-dependent manner (Fig. 2A). The reduction 
of electrophoretic mobility was not due to myogenin modifica- 
tion by reticulocyte lysate components because the electro- 
phoretic mobility was not reduced in the absence of CDC2 
kinase (Fig. 2B, lane 3). Furthermore, the electrophoretic mo- 
bility-shift was completely inhibited by protein kinase inhib- 
itors, 50 ,uM staurosporine (Fig. 2B, lane 4) and 1 mM 
6-dimethylaminopurine (Fig. 2B, lane 5). Thus, the electro- 
phoretic mobility-shift is due to phosphorylation by CDC2 
kinase. 
3.3. Phosphorylation at a proline-directed kinase motif is 
essential for the modljication of myogenin in vivo 
CDC2 kinase is well known to be a proline-directed kinase 
(reviewed in [36,37]) and SP or TP motifs are candidates for 
phosphorylation by CDC2 kinase. There are four SP and TP 
sites in the rat myogenin polypeptide, including serine at resi- 
due number 7 (S7), serine at residue number 43 (S43), threonine 
at residue number 57 (T57), and serine at residue number 170 
(S170). To examine which of these proline-directed kinase mo- 
tifs are responsible for the reduction in electrophoretic mobility 
of myogenin in vivo, the four amino acids at the putative phos- 
phorylation sites were replaced with non-phosphorylating 
amino acids by site-directed mutagenesis in the myogenin 
cDNA as follows: S7 to alanine (A7), S43 to glycine (G43), T57 
to alanine (A57), and S170 to alanine (A170). The mutant 
1 2 3 
Fig. 3. Proline-directed kinase motif-dependent modification of myo- 
genin in vivo. Mutant myogenin cDNA designed to encode a protein 
lacking all four SP/TP sites was constitutively expressed in lOT112 cells. 
Cell clones expressing wild type myogenin (clone GS in lane 2) or 
mutant myogenin lacking SP/TP sites (clone GN21 in lane 3) were 
analyzed. C2C12 myotube lysate was analyzed as a control (lane 1). 
Thirty pg of cellular protein was separated on SDS-PAGE and proc- 
essed for immunoblotting. 
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Fig. 4. One-dimensional phosphopeptide mapping of myogenin phosphorylated in vitro by CDC2 kinase. (A) Expected myogenin peptide fragments 
from N-chrolosuccinimide (NCS) cleavage. Striped bars represent possible fragments excised. NCSl, -2, and -3 correspond to the fragments hown 
in panels (B) and (C). W, positions of tryptophan residues; asterisks, positions of cysteine residues; circles, positions of SPfTP motifs. (B) [%]Cysteine- 
labeled myogenin was immunoprecipitated, separated, and electrotransferred toa nitrocellulose membrane. The labeled myogenin band was processed 
for NCS cleavage. Peptides were separated on Tricine-SDS-PAGE. (C) After incubation with CDC2 kinase in the presence of [r-‘*P]ATP, myogenin 
was immunoprecipitated, separated, and electrotransferred to a nitrocellulose membrane. The “P-labeled band specific for anti-myogenin antibody 
immunoprecipitates [compared to immunoprecipitates with unrelated antibody (anti-GAP antibody)] was analyzed as described in (B). The positions 
of molecular weight markers are shown on the left in panel (B) and the right in panel (C). 
myogenin cDNA designed to encode myogenin lacking the four 
SP/TP motifs (A7G43A57A170) was expressed constitutively in 
lOT1/2 cells. We established several cell lines with various ex- 
pression levels of myogenin and determined the patterns of wild 
type or mutant myogenin (A7G43A57A170) by immunoblot- 
ting. In contrast to wild type myogenin constitutively expressed 
in lOTU2 cells (Fig. 3, lane 2), SP/‘TP motif-deficient myogenin 
was detected as a single band of 36 kDa on SDS-PAGE (Fig. 
3, lane 3). This strongly suggests that phosphorylation of the 
SPiTP motif in myogenin in vitro by CDC2 kinase does in fact 
mimic the modification of myogenin in vivo that causes the 
reduction of electrophoretic mobility. 
3.4. Phosphorylation of serine-43 by CDC2 kinase is responsible 
for the reduction in the electrophoretic mobility of myogenin 
To identify sites in myogenin phosphorylated by CDC2 ki- 
nase, the peptide pattern of myogenin translated in vitro was 
analyzed by chemical cleavage with N-chlorosuccinimide 
(NCS). [?S]Cysteine-labeled myogenin was immunoprecipi- 
tated by anti-myogenin antibody, separated on SDS-PAGE, 
and transferred to a nitrocellulose membrane (Fig. 4B, upper 
panel). Myogenin was detected with an Image Analyzer and a 
strip containing myogenin band was removed and processed 
for NCS cleavage as described in section 2. NCS cleaves pol- 
ypeptides on the carboxyl side of tryptophan residues [34]. Rat 
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myogenin contains two typtophan residues at positions 68, 173 
and thus cleaves into peptides containing amino acids l-68, 
69-173, and 174-224 (Fig. 4A). The expected [35S]cysteine-la- 
beled fragments from myogenin are peptides containing amino 
acids l-173,69-173, l-68, and 69-224 because myogenin con- 
tains 6 cysteine residues at positions 61,65,70,73, 162, and 169 
(Fig. 4A). The apparent molecular weight of the labeled frag- 
ments obtained were 19 kDa, 14 kDa, and 7 kDa, and these 
were termed NCSl, NCS2, and NCS3, respectively (Fig. 4B). 
NCS2 and NCS3 were identified as the myogenin peptides 
comprising amino acids 69-173 and l-68, respectively, from 
their apparent molecular sizes. NCSl was believed to be the 
peptide comprising amino acids 1-173. However, we could not 
exclude the possibility that NCSl corresponds to a peptide 
containing amino acids 69-224 because the apparent molecular 
size of peptide on electrophoresis is sometimes inconsistent 
with the estimated value. To identify phosphorylated peptides, 
myogenin translated in vitro was phosphorylated by CDC2 
kinase in the presence of [Y-~~P]ATP and then immunoprecipi- 
tated with anti-myogenin antibody (Fig. 4C, right lane in the 
upper panel). Phosphopeptide analysis showed all of the NCS 
fragments were phosphorylated by CDC2 kinase (Fig. 4C). 
Therefore, multiple amino acids in myogenin are 
phosphorylated by CDC2 kinase and these sites reside in the 
regions comprising amino acids l-68 (NCS3) and 69-173 
(NCS2). 
In order to determine the CDC2 kinase phosphorylation 
sites, three of the four amino acids at the putative phosphoryl- 
ation sites were replaced with non-phosphorylating amino acids 
by site-directed mutagenesis. Complementary DNA encoding 
wild type or mutant myogenin was used as a template for in 
vitro transcription and then wild type and mutant myogenins 
were produced by in vitro translation. Mutant myogenin pro- 
teins except A7G43A57A170 were designed to contain a single 
proline-directed kinase motif. Wild type or mutant myogenin 
was incubated with active CDC2 kinase in the presence of ATP, 
immunoprecipitated with anti-myogenin antibody, and trans- 
ferred to PVDF membranes. The membranes were then probed 
with anti-myogenin antibody. The electrophoretic mobility 
of myogenin on SDS-PAGE was reduced only in wild type 
and A7A57A170, whereas the mobilities of the other mutants 
(A7G43A57A170, G43A57A170, A7G43A170, and A7G43A57) 
did not change (Table 1). The phosphorylation site resulting in 
the reduction of electrophoretic mobility of myogenin was 
shown clearly to be S43. 
Table 1 
Electrophoretic mobility of mutant myogenin after phosphorylation by 
CDC2 kinase in vitro 
Mutant name Positions of amino acids Band-shift 
I 43 51 170 
Wild type S S T S + 
A7G43A57Al70 A G A A - 
G43A57A170 S G A A - 
AlA5lAllO A S A A + 
A7G43A110 A G T A - 
AlG43A51 A G A S - ._ _ _.__ 
Wild tvue and mutant mvonenin were incubated with active CDC2 
kinase-& the presence of ImM ATP and then separated on SDS- 
PAGE. The presence (+) or absence (-) of the slow migrating form of 
myogenin was determined. 
Fig. 5. Reduction of electrophoretic mobility dependent on S43 in 
myogenin in vivo. Wild type or mutant myogenin in which S43 was 
replaced by glycine (G43) was transiently expressed in COS-7 cells. 
Myogenin was detected by immunoblotting. Fifty pug of cellular protein 
was analyzed. Lane 1, C2C12 myotubes; lane 2, wild type myogenin 
expressing COS-7 cells; lane 3, the S43 mutant expressing COS-7 cells. 
3.5. The in vitro CDC2 kinase phosphorylation site is essential 
for the modiJication of myogenin in vivo 
In order to demonstrate that S43 is the essential amino acid 
for the reduction of electrophoretic mobility in living cells, a 
mutant myogenin cDNA designed to replace S43 with glycine 
(G43) was constructed and transiently expressed in COS-7 cells. 
Myogenin was detected as a pair of bands in wild type myo- 
genin-expressing COS-7 cells (Fig. 5, lane 2) as shown in C2C12 
cells. In contrast, only the fast migrating form of myogenin was 
present in GU-expressing COS-7 cells (Fig. 5, lane 3). Thus, 
S43 appears to be essential for the modification of myogenin 
in vivo that results in the reduction in electrophoretic mobility 
through phosphorylation. 
3.6. Serine-I 70 is another candidate CDC2 kinase 
phosphorylation site in vitro 
Phosphopeptide mapping showed another CDC2 kinase 
phosphorylation site in NCS2 corresponding to the region com- 
prising amino acids 69-173 (Fig. 4C). This fragment includes 
a single proline-directed kinase phosphorylation site, S170. We 
found that a p-galactosidase myogenin carboxyl-terminal do- 
main (amino acids 134-224) fusion protein is phosphorylated 
by CDC2 kinase in vitro (data not shown). Furthermore, a 
synthetic peptide comprising amino acids 165-178 of myo- 
genin, MP3b, is a suitable substrate for CDC2 kinase. Active 
CDC2 kinase phosphorylates an SP motif-containing peptide, 
MP3b, very efficiently whereas the serine or threonine residues 
in Kemptide or casein kinase II substrate peptide were not 
phosphorylated (Fig. 6). The results suggest hat CDC2 kinase 
phosphorylates peptides in a proline-directed kinase motif-de- 
pendent manner. Thus, S170 is assumed to be another CDC2 
kinase phosphorylation site in vitro, which is not responsible 
for the electrophoretic mobility-shift of mytogenin (Table 1). 
4. Discussion 
It has been widely reported that the function of transcription 
factors is directly regulated by phosphorylation (reviewed in 
[38]). MyoD family members are skeletal muscle-specific tran- 
scription factors reported to be phosphoproteins [22,39,40]. 
Extracellular signaling molecules, including bFGF, TGFb, and 
serum, but not insulin, suppress the function of myogenic deter- 
mining factors (reviewed in [lo]), presumably through phos- 
phorylation [20,41]. The DNA binding activity of myogenin is 
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Fig. 6. Phosphorylation of myogenin peptide by CDC2 kinase in vitro. 
Synthetic peptides were incubated with active CDC2 kinase in the 
presence of [Y-~‘P]ATP at 30°C for 60 min. Reaction mixtures con- 
tained no peptide substrate (w/o pep) or 500 PM of the indicated 
peptide. MP3b, the peptide comprising amino acids 165-178 of myo- 
genin; Kemptide, CAMP-dependent protein kinase substrate peptide; 
CKIIP, casein kinase II substrate peptide. Averages of duplicate sam- 
ples are shown. 
repressed through phosphorylation of its basic region by PKC, 
a downstream component of bFGF in non-myogenic cells [20]. 
Overexpressed myogenin in COS cells is phosphorylated by 
PKA but myogenin function is not affected [21]. Here we pro- 
vide direct evidence that myogenin undergoes multiple phos- 
phorylation during myogenesis, although previous studies 
report the phosphorylation of myogenin in proliferating non- 
myogenic cells. The present results imply that myogenin func- 
tion is regulated through phosphorylation during myogenesis. 
Furthermore, we found that phosphorylation of S43 is re- 
sponsible for the reduction in the electrophoretic mobility of 
myogenin in vivo as well as in vitro. This phosphorylation 
would cause a significant change in the protein structure of 
myogenin and affect its function. Schwarz et al. [42] showed 
that the amino-terminal domain including S43 is important for 
the transcriptional activity of myogenin. Thus, it is conceivable 
that phosphorylation of S43 negatively regulates the transcrip- 
tional activity of myogenin although S43 phosphorylation does 
not suppress its DNA binding activity (Hashimoto, unpub- 
lished). Functional changes in myogenin by S43 phosphoryla- 
tion are currently under investigation in our laboratory. 
In addition to S43, here we propose S170 as another possible 
phosphorylation site by CDC2 kinase in vitro (Fig. 4). S170 
resides in the carboxyl terminal activation domain of myogenin 
[42]. The amino acid sequence around S170, SCSPEW, is con- 
served among avian and mammalian myogenins [43] whereas 
the other three SP/TP motifs are present only in mammals. We 
currently investigate the role of S170 phosphorylation in the 
regulation of myogenin function including suppression of its 
transcriptional activity. We are also pursuing the possibility 
that S7 and T57 in other SP/TP motifs undergo phosphoryla- 
tion during myogenesis. 
In vitro system, CDC2 kinase modifies myogenin by phos- 
phorylating S43, a process that also occurs in vivo. Hyper- 
phosphorylated myogenin (the SU-phosphorylated form) is 
present throughout myogenesis although CDC2 kinase is 
promptly down-regulated in differentiating myoblasts ([44,45], 
Hashimoto, unpublished). Thus, another proline-directed ki- 
nase would phosphorylate S43 in vivo. Possible candidates are 
members of the CDC2 family and mitogen-activated protein 
(MAP) kinases because these kinases sometimes phosphorylate 
the same protein sites as CDC2 kinase [37]. Our mutant myo- 
genin would be useful in identifying the myogenin kinase re- 
sponsible for the phosphorylation of S43, assumed to be a 
negative regulator of myogenin. Phosphorylation of proline- 
directed kinase motifs is also reported in cytoskeletal proteins 
from striated muscle, dystrophin [46] and titin [47]. Proline- 
directed kinases would play multiple roles in myogenic differen- 
tiation through phosphorylation of various molecules. There is 
no doubt that the phosphorylation of myogenin plays a critical 
role in myogenic differentiation. 
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